Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

14.46
+0.07000.49%
Post-market: 14.460.00000.00%19:08 EDT
Volume:2.79M
Turnover:40.10M
Market Cap:1.48B
PE:-1.57
High:14.63
Open:14.48
Low:13.87
Close:14.39
Loading ...

Biohaven Is Maintained at Overweight by JP Morgan

Dow Jones
·
18 Jun

Biohaven, Bexorg Collaborate to Develop CNS Therapies

MT Newswires Live
·
11 Jun

Bexorg Announces Research Collaboration With Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

THOMSON REUTERS
·
11 Jun

Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates

MT Newswires Live
·
05 Jun

Morgan Stanley Keeps Their Buy Rating on Biohaven Ltd. (BHVN)

TIPRANKS
·
30 May

Biohaven Ltd. Launches Global Phase 2/3 Trial for Novel Parkinson's Disease Therapy BHV-8000, Targeting Neuroinflammation

Reuters
·
29 May

Biohaven Enrolls First Patient Into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation With Novel Brain-Penetrant Tyk2/Jak1 Inhibitor

THOMSON REUTERS
·
29 May

Biohaven announces ‘positive’ TRAP degrader data

TIPRANKS
·
29 May

Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy

Reuters
·
29 May

BRIEF-Biohaven Presents Oncology Program Updates And Preliminary Clinical Data

Reuters
·
28 May

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates (Adcs) Incorporating Novel Topoix Payload With Potential to Treat a Wide Variety of Tumors

THOMSON REUTERS
·
28 May

Biohaven Ltd. Unveils Promising Early Clinical Data for Innovative ADCs in Cancer Treatment

Reuters
·
28 May

BUZZ-U.S. STOCKS ON THE MOVE-Plug Power, BGC Group, Paramount Group

Reuters
·
20 May

Biohaven Cut to Sector Perform From Outperform by RBC Capital

Dow Jones
·
19 May

Biohaven Has Lots Of Shots, Too Many Risks, RBC Says

MT Newswires Live
·
19 May

BUZZ-Biohaven falls after RBC downgrades on regulatory uncertainty

Reuters
·
19 May

RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $21 From $54, Keeps Speculative Risk

MT Newswires Live
·
19 May

Stock Track | Biohaven Pharmaceutical Plunges 6.74% Pre-Market Following RBC Downgrade and Price Target Cut

Stock Track
·
19 May

Stock Track | Biohaven Pharmaceutical Plunges 6.36% as FDA Extends Review of Key Drug Application

Stock Track
·
16 May

Stock Track | Biohaven Pharmaceutical Plummets 5.11% After RBC Cuts Price Target

Stock Track
·
16 May